Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeting The Tongue: Helius Medical’s Unique Approach To Neuromodulation Tested In Trials

Executive Summary

Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.

You may also be interested in...



FDA Rejects Helius’ De Novo Application For PoNS To Treat Brain Injury

Helius Medical announced on April 10 that the US FDA has declined its de novo application for treating brain injury with its Portable Neuromodulation Stimulator.

Helping The Blind To See: Medtech Start-Ups Focus On Vision Restoration

In recent years, medtech start-ups have made great strides in developing technologies to treat eye disease such as cataracts, diminishing vision, and even dry eye. But the greatest leaps – or the most life changing – may have been executed by companies such as Second Sight Medical Products Inc. and Wicab Inc. that are finding ways to actually help blind people see.

Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market

Emerging technologies in peripheral nerve stimulation are expected to play a pivotal role in opening up new markets and driving growth in the neuromodulation device market in the years ahead. As a result, the pipeline is rich with products designed to address a growing number of patients with long-term pain and other chronic conditions, many of whom have no other treatment options.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel